Rod-shape of most bacteria is maintained by the elongasome, which 25 mediates the synthesis and insertion of peptidoglycan into the cylindrical part 26 of the cell wall. The elongasome contains several essential proteins, such as 27
Introduction 57
Bacterial cells are surrounded by a peptidoglycan layer that maintains their 58 shape and protects them from bursting due to the osmotic pressure. The 59 biosynthesis of peptidoglycan is the target of many antibiotics that are used in 60 clinical therapies for bacterial infections. The spread of antibiotic resistant 61 pathogens calls urgently for the development of novel antibiotics. In depth 62 knowledge on peptidoglycan synthesis will aid in the development of effective 63 screening assays to select cell wall synthesis inhibitors. Peptidoglycan is a 64 mesh-like heteropolymer of glycan chains of GlcNAc-MurNAc-peptide 65 subunits that are connected by peptide cross-links (1). Peptidoglycan 66 synthesis begins in the cytoplasm with synthesis of UDP-GlcNAc and UDP-67
MurNAc-pentapeptide (2) . Two following membrane steps, catalyzed by MraY 68 and MurG, assemble the precursor lipid II (3, 4) , which is flipped to the 69 periplasmic side of the cytoplasmic membrane by lipid II flippase(s) MurJ 70 and/or FtsW (5-7). GlcNAc-MurNAc pentapeptide units are polymerized into 71 glycan chains and the peptides are cross-linked to bridge the glycan stands 72 by peptidoglycan synthases to expand the peptidoglycan layer while the 73 itself, MreB and MreC (28, 29) ( Fig.1b) , and these interactions are essential to 99 maintain bacterial morphology (28, (30) (31) (32) . RodA and PBP2 form a stable 100 subcomplex (33) and provide GTase and TPase activity, respectively, during 101 cylindrical peptidoglycan synthesis (9, 34, 35 ). This subcomplex also shows a 102 circumferential motion that is similar to that of MreB. The bifunctional GTase-103
TPase PBP1A interacts with PBP2 and stimulates its activity (18). Because 104 PBP1A moves independently of the rotation of PBP2 and MreB, it is thought 105 not to be part of the core elongasome (18, 36) . However, the function and role 106 of most elongasome proteins are still poorly understood. How peptidoglycan 107 synthesis is activated and regulated during elongation is still the key question. 108
In this study, combining genetics, microscopy and Förster Resonance Energy 109
Transfer (FRET), we investigated the functions of, and interactions between, 110 these core elongasome proteins. The transfer of energy between a donor 111 fluorescent-protein fusion and an acceptor fluorescent-protein fusion (FRET) 112 is very sensitive to distance, which even allows the detection of 113 conformational changes that affect this distance (7) . Our results indicate that 114
MreC and MreD modulate the interaction between PBP2 and RodA in 115 oppositely, which likely reflects a mechanism of elongasome activation and 116 regulation. 117
118
Results 119
RodA and PBP2 activities are not essential for their interaction 120
RodA and PBP2 form a stable peptidoglycan synthesizing subcomplex in the 121 cytoplasmic membrane as detected by FRET (33). To investigate whether this 122 interaction relies on their enzymatic activities, RodA R109A and RodA Q207R 123 versions, which were predicted to be inactive based on studies on its 124 homologue FtsW, were constructed ( Supplementary Fig. 1) (5, 38) . As 125 expected, these mutants could not complement the temperature sensitive 126
RodA strain LMC882 at the non-permissive temperature, and the RodA Q207R 127 variant even showed dominant negative effects at the permissive temperature 128 ( Fig. 2a) . Subsequently, N-terminal mCherry fused versions (33, 34) of the 129 inactive RodA proteins were expressed to test their interaction with mKO-130 PBP2 WT by FRET (Fig. 2b) . In our FRET system, the direct fused mCherry-131 mKO tandem was used as positive control (33). To account for possible 132 interactions between proteins due to crowding in the cytoplasmic membrane, 133 an integral membrane protein unrelated to peptidoglycan synthesis, GlpT 3, 34 , 134 was fused to mKO, and its interaction with mCh-RodA was detected as 135 negative control. The acceptor FRET efficiency values (EfA) of all FRET 136 samples were calculated using our previously published mKO-mCh FRET 137 spectral unmixing method (33) ( Supplementary Fig. 2a ). An EfA value of 31.0 138 ± 4.0% was observed for the tandem control ( Fig. 2b and Table 1) , which is 139 comparable to the published data (33). An EfA value of 1.1 ± 3.5% was 140 observed for the RodA-GlpT negative control ( Fig. 2b and Table 1 ). FRET 141 experiments with PBP2 WT and RodA R109A or RodA Q207R yielded EfA values of 142 12.5 ± 1.9% and 12.7 ± 1.2%, respectively, which are comparable to the EfA 143 value of 12.7 ± 1.7% of wild type RodA, indicating an interaction between 144 PBP2 WT and all RodA versions ( Fig. 2b , Supplementary Fig 2a and Table 1) . 145
To determine whether the activity of PBP2 was required for the interaction 146
with RodA, we expressed the inactive variant PBP2 S330C , which is not able to 147 bind benzylpencillin (35). PBP2 S330C had a strong dominant negative effect 148 during the complementation in the PBP2 temperature sensitive strain LMC582 149 ( Fig. 2c ), while the detected EfA value of PBP2 S330C -RodA WT remained 10.9 ± 150 0.5%, which was slightly below the EfA value of PBP2 WT -RodA WT (Fig. 2b and 151 Table 1 ). These results imply that the activities of RodA and PBP2 are not 152 needed for their interaction. 153
154
The transmembrane and periplasmic parts of PBP2 contribute to its 155 interaction with RodA 156
To reveal which part of PBP2 interacts with RodA, two domain swap mutants 157 of PBP2 were constructed. The cytoplasmic N-terminus (NT) and or the N-158
terminal region with the transmembrane-helix (NT-TMH) of PBP2 were 159 replaced by the corresponding N-terminal stretches of MalF, a bitopic 160 membrane protein that has been previously used in domain swap studies 161 (39-41), to yield MalFNT PBP2 and MalF37 PBP2, respectively ( Fig. 3a ). Both 162 versions of PBP2 were able to localize to the membrane but showed 163 dominant negative effects, indicating the essentiality of the replaced parts ( Fig.  164 3b). The replacement of the NT of PBP2 did not change its interaction with 165
RodA, as the detected EfA value remained 14.4 ± 1.1%, which was not 166 significantly different compared to that of the interaction between RodA and 167 wild type PBP2 ( Fig. 3c , Table 1 and Supplementary Fig. 2b ). However, 168 replacement of the TMH of PBP2 significantly reduced the EfA value between 169 PBP2 and RodA to 8.2 ± 1.3%, which reflected an apparent distance increase 170 from 8.6 nm to 9.8 nm between the two proteins (42) ( Fig. 3c and Table 1) . 171
This decrease in distance was not caused by a change in amount of 172 measured fluorescence for the RodA and PBP2 fusions expressed in the cells 173 ( Supplementary Fig. 2b ), or due to the shorter transmembrane helix after 174 replacement (Fig. 3a) . The average rise per residue in transmembrane helices 175 is 0.15 nm (43), therefore the two amino acid residues shorter helix in 176 MalF37 PBP2 ( Fig. 3a) could maximally change the distance between donor and 177 acceptor fluorophores by 0.3 nm. The still considerably higher EfA value 178 compared to the negative control indicates that the transmembrane helix 179 alone is not sufficient for the interaction between PBP2 and RodA and that the 180 periplasmic domain of PBP2 is also involved in this interaction ( Fig. 3d ). 181 182
MreC interacts with PBP2 and affects PBP2-RodA interaction 183
A recent study of PBP2-MreC from Helicobacter pylori showed two different 184 structural conformations of PBP2 in the MreC-bound and unbound forms, 185 respectively 43 ( Fig. 4 a) . The authors proposed that the binding of MreC to the 186 periplasmic hydrophobic zipper of PBP2 induces a conformational change in 187 PBP2 and a switch from an off state into an on state (44). In our FRET system 188 about 1000 copies of the mKO fusion proteins per cell are expressed from a 189 plasmid (45). The ~180 endogenous copies of MreC molecules (46) are not 190 sufficient to activate the majority of the by plasmid expressed mKO-PBP2 191 molecules. Therefore, we hypothesize that most of the mildly overexpressed 192 PBP2 versions remain in the off state conformation (Fig. 4b, left ). We 193 reasoned that the interaction between PBP2 and RodA could be sensitive to We next we employed a three-plasmids-FRET system that expressed MreC 203 from a third plasmid when testing the interaction between PBP2 and RodA 204 ( Fig. 4d , Table 2 and Supplementary Fig. 4 ). A control strain contained an 205 empty plasmid instead of the MreC-expression plasmid. In the presence of the 206 empty plasmid, the calculated EfA values for the tandem (positive control) and 207
RodA-GlpT (negative control) were 30.4 ± 1.8% and 2.3 ± 1.3%, respectively 208 ( Fig. 4d and Table 2 ). These EfA values remained unchanged in the presence 209 of MreC expressed from the third plasmid ( Fig. 4d and Table 2 ). Interestingly, 210
the EfA value for the RodA-PBP2 interaction was significantly reduced to 4.9 ± 211 0.6% in the presence of MreC, compared with the EfA of 8.8 ± 1.1% in the 212 presence of empty plasmid ( Fig. 4d and Table 2 ). These results indicate that 213
MreC changes the interaction between PBP2 and RodA, which would be 214 consistent with an conformational change of PBP2 from the off state to the on 215 state proposed from the crystal structures (44) ( Fig. 4b, middle) . During our study, we noticed that overexpression of MreC caused 220 morphological defects of the wild type strain, increasing the diameter of E. coli 221 cells ( Fig. 4e and Supplementary Fig. 5 ). Interestingly, the co-expression of 222
MreD together with MreC suppressed these morphological defects and 223 restored the wild type phenotype ( Fig. 4e and Supplementary Fig. 5 ). To 224 further investigate this effect, we aimed to express an N-terminal functional 225 mCherry fusion of MreD (30) which is an integral membrane protein with 6 226 predicted transmembrane helices and both termini localized in the cytoplasm 227 ( Supplementary Fig. 6 ). Consistent with this topology model we readily Table 1  237 and Supplementary Fig. 3 ). Subsequently, the interaction between MreC and 238 PBP2 was measured by FRET in the presence of MreD. The calculated EfA 239 between MreC and PBP2 was significantly reduced from 5.1 ± 1.2% to 3.3 ± 240 0.5% (p=0.0078) when MreD was co-expressed ( Fig. 4c , Table 1 and 241 Supplementary Fig. 3 ). Since MreC reduced the EfA of RodA-PBP2 from 8.8 ± 242
1.1% to 4.9 ± 0.5%, it was possible that MreD altered the effect of MreC on 243 the RodA-PBP2 interaction. Therefore, the three-plasmid FRET experiment 244 was applied to detect the interaction between RodA and PBP2 in the 245 presence of MreCD. Interestingly, the EfA value of RodA-PBP2 was restored 246 to 9.2 ± 1.5%, which was comparable with the EfA in the presence of the third, 247 empty plasmid ( Fig. 4d and Table 2 ). These combined results suggest a 248 regulatory mechanism by which MreC interacts with PBP2 and changes its 249 The cytoplasmic part of PBP2 is important for the interplay with the 255
MreCD proteins 256
As showed before, the cytoplasmic NT part of PBP2 has an essential 257 unknown function rather than being involved in the RodA-PBP2 interaction 258 ( Fig. 3 ). We considered that the NT of PBP2 might be important for its self-259
interaction and or interactions with other partner proteins. However, the EfA 260 values of MalFNT PBP2 with wild type PBP2, MreC and MreD were not different 261 from those of wild type PBP2 ( Fig. 4d , Supplementary Fig. 7 and Table 1) . 262
Interestingly, the EfA value of the interaction between MreC and wild type 263 PBP2, but not the MalFNT PBP2, was reduced by the co-expression of MreD 264 ( Fig. 4d , Table 1 and Supplementary Fig. 4c ). Similarly, in the three-plasmid 265 FRET experiments, MreD was not able to suppress the MreC-mediated 266 change in the MalFNT PBP2-RodA interaction; the EfA value of RodA-MalFNT PBP2 267 FRET remained at 5.5 ± 1.7% in presence of MreCD, rather than being 268 restored to 9.2 ± 1.5% as in the RodA-PBP2 WT experiments ( Fig. 4d , Table 2  269 and Supplementary Fig. 4c ). Together, these results indicate that the 270 cytoplasmic part of PBP2 plays an important role in the MreCD-mediated 271 regulation of the interaction between PBP2 and RodA. 272
273

MreCD proteins do not alter PBP2 self-interaction 274
So far our results has shown that MreC and MreD have opposite effects on 275 the interaction between RodA and PBP2. In contrast, the interaction between 276 two PBP2 molecules (17) was not significantly affected upon overexpression 277
of MreC or MreCD, as the calculated EfA values for the PBP2-PBP2 278 interaction remained unchanged compared to the values for the expression of 279 the third empty plasmid ( Fig. 4d and Table 2 ). RodA was also found to interact 280 with itself (Table 1 and Supplementary Fig. 7 ). Likely PBP2 and RodA function 281 as a complex of dimers, which might also allow simultaneously synthesis of 282 multiple glycan strand as has been proposed (47-49). 283 284
Effect of mecillinam on the interaction between RodA and PBP2 285
As showed above, both the transmembrane helix and periplasmic part of 286 PBP2 contribute to its interaction with RodA ( Fig. 3 ). The binding of MreC to 287 the periplasmic hydrophobic zipper domain of PBP2, which presumably 288 changes the conformation of PBP2 from off state to on state, reduces the 289 detected EfA between RodA and PBP2 ( Fig. 4d and e ). Interestingly, the 290 PBP2 specific inhibitor mecillinam, also caused a reduction in the FRET 291 efficiency of the interaction between RodA and PBP2. The RodA-PBP2 WT 292 interaction pair yielded a reduced EfA of 8.6 ± 1.1% in the presence of 293 mecillinam (33), comparing with the EfA of 12.7 ± 1.7% without mecillinam ( Fig.  294 2, Table 1 and Supplementary Fig. 8 ). Since mecillinam binds specifically to 295 the periplasmic TPase active site of PBP2, a possible explanation could be 296 that binding of mecillinam reduces the affinity between the periplasmic parts 297 of PBP2 and RodA, but does not interfere with the interaction between their 298 transmembrane regions. Indeed, after replacing the transmembrane helix of 299 PBP2 to abolish this part of the interaction (RodA-MalF37 PBP2), mecilinam 300 further reduced the EfA value to 3.0 ± 2.0% ( Supplementary Fig. 8 and Table  301 1), consistent with an almost complete loss of the interaction between RodA 302 and MalF37 PBP2. That mecillinam causes disruption of only one out of two 303 interacting regions between PBP2 and RodA is also in agreement with the 304 observations that it does not disrupt the structure of the elongasome (50). The 305 inactive mutant PBP2 S330C , which cannot bind benzylpenicillin (35), still 306 responded to mecillinam and showed a similar EfA reduction as PBP2 WT 307
( Supplementary Fig. 8 and Table 1 ). This suggests that although the inactive 308 mutant PBP2 S330C does not bind mecillinam covalently, it still interacts with it. 309 310 PBP2 L61R stays in the off state and activates RodA 311
A recent study reported a version of PBP2 in which Leu61 was replaced by 312
Arg (PBP2 L61R ) that could suppress an MreC defect, and was proposed to 313 stay in the on state conformation mimicking activation by MreC (51). If this 314 would be the case, the RodA-PBP2 L61R pair would be expected to have a 315 reduced FRET efficiency, since the MreC activated RodA-PBP2 WT pair 316 resulted in a reduction in FRET efficiency (Fig 4d) . Therefore, we constructed 317 an N-terminal mKO fusion of PBP2 L61R to test the interactions with its partner 318 proteins. Surprisingly, the EfA for RodA-PBP2 L61R remained 12.8 ± 2.8%, 319 which was comparable with the EfA of RodA-PBP2 WT that was presumably in 320 the off state ( Fig. 5a and b, Table 1 and Supplementary Fig. 9a ). Mecillinam 321 reduces the EfA value of the RodA-PBP2 L61R interaction to 9.7± 2.2%, which 322 was also comparable with its effect on the RodA-PBP2 WT interaction (Table 1  323 and Fig. S8 ), indicating that the TPase active side of PBP2 L61R is still 324 accessible to mecillinam. Unfortunately, the co-expression of PBP2 L61R 325 together with either MreC or MreD alone, or both together, was not possible in 326 most cases, as FRET cells repeatedly lost the mKO-PBP2 L61R signal upon 327 induction (Table 1 ), suggesting toxicity of these combinations. The cells did 328 not lose the mKO signal in only two out of six attempts to co-express MreC 329 and PBP2 L61R . Of those samples the calculated EfA value of the MreC and 330 PBP2 L61R pair remained at 5.4 ± 1.7%, which was comparable with MreC-331 PBP2 WT ( Fig. 4a and Table 1 ). These results suggest that the hyperactive 332 mutant PBP2 L61R likely behaves similarly as wild type PBP2 in the interaction 333 with its partner proteins. 334
335
Having observed these unexpected results, we continued to further 336 characterize the hyperactive PBP2 L61R . Consistent with its reported 337 functionality (51), we observed that mKO-PBP2 L61R was capable to support 338 growth of the PBP2(TS) strain LMC582 at the non-permissive temperature 339 ( Supplementary Fig. 9b ). However, the expression of mKO-PBP2 L61R resulted 340 in longer and thinner cells ( Fig. 5c and Supplementary Fig. 9c ), and in 341 reduced sensitivity of cells to the MreB inhibitor A22 (Fig. 5c ) as reported (51). 342
Interestingly, cells expressing PBP2 L61R were hypersensitive to mecillinam 343 ( Fig. 5c and d) . These results indicate potential defects in the peptidoglycan 344 layer of cells expressing PBP2 L61R , and these defects may be tolerable under 345 undisturbed growth conditions but are exacerbated in the presences of 346 mecillinam. Considering that PBP2 L61R stimulates the GTase activity of RodA 347 in vitro (51) and our results on the cellular interactions, it was possible that the 348 L61R exchange in PBP2 enhances only the activity of RodA and has no effect 349 on PBP2's TPase activity. In vitro peptidoglycan synthesis experiments 350 showed that inactivation of PBP2 by mecillinam resulted in longer glycan 351 chains synthesized by a PBP1A-PBP2 complex (18), hence we wondered 352
whether the presence of PBP2 L61R affected peptidoglycan synthesis in the cell. 353
We prepared peptidoglycan and analyzed its composition from cells 354 expressing PBP2 L61R , wild type PBP2, and the control membrane protein GlpT. 355
As predicted, the peptidoglycan from all strains retained a similar extent of 356 peptide cross-linkage. By contrast, only the peptidoglycan from the PBP2 L61R 357 expressing cells contained unusually long glycan chains with a mean length 358 ~52 disaccharide units ( Table 3 ). The peptidoglycan of the strain 359 overexpressing wild-type PBP2 had a mean glycan chain length of ~38 units, 360 and the mean glycan chain lengths of the other strains were between 40-43 361 disaccharide units (Table 3 , Supplementary Table 3 ). A stimulating effect of 362 PBP2 L61R on RodA's GTase activity would be consistent with the previously 363 observed A234T mutation in RodA that suppressed the morphological defects 364 of MreC mutants (51), and would also explain why PBP2 L61R could only poorly 365 restore survival and rod-shape in cells depleted of MreCD or RodZ (51). The 366 tolerance to A22 and changes in MreB dynamics in the PBP2 L61R background 367 (51) could also be explained by the enhanced RodA GTase activity by 368 PBP2 L61R ; a direct interaction between RodA and MreB was detected with a 369
EfA value of 5.5% ± 1.7% (Table 1 and Supplementary Fig. 10 ). All together 370 these results indicate that the 'hyperactive' PBP2 L61R likely has unchanged 371
TPase activity itself but is probably in the off state conformation in the 
MreCD proteins regulate the interaction between RodA and PBP2 396
In this study, we showed that RodA and PBP2 form a subcomplex 397 independent of their biochemical activities (Fig. 2) . This interaction requires 398 the transmembrane helix and periplasmic parts of PBP2 (Fig. 3) . In vivo FRET 399 experiments revealed that MreC interacts with directly with PBP2, which 400 modulated the interaction between PBP2 and RodA (Fig. 4) . Surprisingly, 401
MreD also interacts with PBP2 and but has an opposite effect, as it reverses 402 the PBP2-RodA interaction change stimulated by MreC (Fig. 4) . This is similar 403 to the regulation of septal peptidoglycan synthesis where FtsN interacts with 404 itself and accumulates at midcell (56, 57), and this accumulation is assumed 405 to abolish the suppression of the peptidoglycan synthesis complex FtsW-406 PBP3-PBP1B by FtsBLQ. When comparing the cellular numbers of these 407 proteins synthesized per generation (46), we noticed that the average number 408
of FtsN molecules per cell is about 2 times higher than that of FtsBLQ and 409
FtsW-PBP3 proteins. The number of MreC molecules is also about 2 times 410 higher than that of MreD and PBP2-RodA molecules (46). MreC, but not MreD, 411
is also reported to interact with itself, and the structural data showed that two 412 molecules of MreC bind to one PBP2 molecule (44). Together with these 413 published data, our results indicate that the balance between the MreC and 414
MreD determines the nature of the interaction between PBP2 and RodA. 415
Structural data show that the interaction between MreC and PBP2 causes a 416
conformational change in PBP2 that was suggested to correspond to its RodA activities, and cause morphological defects ( Fig. 4e and Supplementary 427 Fig. 7) . 428
Based on our observations, we propose a model for the regulation of 429 PBP2 (elongasome) activity and cylindrical peptidoglycan synthesis (Fig. 6) . pXL40, pXL44, pXL48, pXL56 and pXL63 . Plasmids pXL36 and 463 pXL40 that expressing mCherry-fused RodA R109A and RodA Q207R were 464 generated from pSAV047-RodA by mutagenesis PCR using primer pairs 465 priXL61-priXL61 and priXL69-priXL70, respectively. To construct non-fused 466 version of RodA variants, wild type rodA gene was amplified using primer 467 priXL59 and priXL60 from the MG1655 genomic DNA and ligated into empty 468 pSAV057 vector, to generate plasmid pXL63. The two mutants plasmids were 469 generated in the same way as descripted above from pXL63. mKO fused 470
RodA plasmid pXL56 was constructed by cutting and pasting the rodA gene to amplify the ptrcdown promoter. Primer pairs pXL284-priXL297 and priXL284-500 priXL298 were used to amplify the mreCD and mreD genes, respectively. 501 502
Bacterial growth, morphology and protein localization 503
For general growth experiments in rich medium, overnight cultures (37 °C) 504 were diluted 1:1000 into fresh LB medium with 0.5% glucose and the required 505 antibiotics, and grew to OD600 around 0.2 at 37 °C. Cultures were further 506 diluted 1:5 into fresh LB medium with required antibiotics, and induced with 15 507 μM IPTG for 2 mass doubling at 37 °C (OD600 reached around 0.2). 508
509
For complementation experiments, temperature sensitive strains expressing 510 the mutant plasmids were grown as described above at 30 °C. Cultures were 511 further diluted 1:5 into fresh LB medium with required antibiotics, and induced 512 with 15 μM IPTG for 2 mass doubling at 30 °C and 42 °C, respectively (OD600 513 reached around 0.2). 514 515 After induction, cells were fixed with FAGA (2.8 % formaldehyde and 0.04 % 516 glutaraldehyde, final concentration) for 15 minutes and centrifuged at 7000 517 rpm for 10 min at room temperature. Cell pellets were suspended and washed 518 3 times with PBS (pH7.2) buffer. Subsequently, bacterial morphology and 519 protein localization were imaged by wide field phase contrast and 520 fluorescence microscopy. Specially, cells expressing the mKO fused proteins 521
were firstly matured at 37 °C overnight before imaging by microscopy. 522
523
FRET experiment and data analysis 524
Protein interactions were detected by FRET as described previously (33, 37, 525 62). For the FRET experiments, mCherry and mKO fluorescent proteins were 526 used as acceptor and donor fluorophores, respectively. LMC500 strain was 527 co-transformed with the FRET pairs that were to be detected. In each FRET 528 experiment, the empty-vector reference, mCherry reference, mKO reference 529 were included to be able to calculate the EfA by unmixing of the measured 530 FRET pair spectrum in its individual components; background, mCherry, mKO 531 and sensitized emission spectra. A tandem fusion of mKO-mCherry was used 532 as positive control, and the mCherry-RodA and mKO-GlpT pair was used as 533 negative control. After transformation, FRET strains were firstly grown in LB 534 medium (with antibiotics and 0.5% glucose) overnight at 37 °C, and diluted 535 1:1000 into fresh medium and grown to OD600 around 0.2 at 37 °C. 536
Subsequently, FRET strains were diluted 1:500 into Gb4 medium and grown 537 to steady state at 28 °C (OD450 was kept below 0.2). All FRET strains were 538 induced with 15 μM IPTG (and treated with mecillinam at 2 mg·L -1 539 concentration as indicated) for two mass doubling before FAGA fixation. After 540 fixation, FRET cells were pelleted by centrifugation at 7000rpm at room 541 temperature and washed 3 times with PBS buffer (pH 7.2). Then all samples 542 were incubated at 37 °C overnight and stored at 4 °C for 1 extra day before 543 measured with spectrofluorimeter (Photon Technology International, NJ). 544
Emission spectra of acceptor and donor fluorophores were measured through 545 6-nm slit widths with 1 second integration time per scanned nm for 3 times 546 averaging. Filters 587/11 nm (587/11 nm BrightLine single band-pass filter, 547
Semrock, New York, NY, USA) and 600nm long-pass (LP) filter (Chroma 548 Technology Corp., Bellows Falls, VT) were used for excitation and emission of 549 acceptor fluorophore (mCherry), while 541/12 nm (Semrock) and 550 nm long 550 pass (Chroma) filters were used for mKO excitation and emission, 551 respectively. For calculation, measurement of PBS buffer was subtracted from 552 all samples, and the empty-cell reference was subtracted from the donor and 553 acceptor spectra. The FRET efficiencies were calculated as described 554 previously (37, 62). 555 556 For three plasmids FRET, a third plasmid (expressing MreC or expressing 557
MreCD both) was introduced into the whole two plasmids FRET system. 558
Empty pSG4K5 vector was also introduced as a control to correct for the 559 reduction in FRET efficiency due to the burden of maintaining three plasmids. 560 561
Spot assay 562
To test the sensitivity of E. coli strains to A22 and mecillinam, LMC500 strain 563 was transformed with pWA004 (PBP2 WT ) or pXL159 (PBP2 L61R ). Strains 564 expressing each construct were grown in LB medium as descried above 565 without induction. Cell cultures were diluted with varying dilution factors (Fig.  566   4C) . A drop of 10 μl cell culture from each dilution was loaded on the LB agar 567 dish (with chloramphenicol, 15 μM IPTG, 10 μg·mL -1 A22 or 2 μg·mL -1 568 mecillinam) and incubated overnight at 37 °C. 569 570
Peptidoglycan analysis 571
Peptidoglycan sacculi were prepared from E. coli cells, digested with cellosyl 572 (kind gift from Hoechst, Germany), reduced with sodium borohydride and 573 analyzed by high pressure liquid chromatography as described (Separation 574 and quantification of muropeptides with high-performance liquid 575 chromatography) (63 2, 3 Here all measured positive and negative controls are averaged. In the figures the controls are included that belong to the corresponding measurements. 4 RodA without superscript represent the wild type version. 5 mCh-MreB SW is a sandwich fusion of MreB-mCherry-MreB (33). 6, 7 MreC and MreD were expressed from one plasmid, and MreC was fused to mCherry while MreD was non-fused. 
Parameter
Identified interactions between elongasome proteins from previous interaction studies (1-5).
Double arrowed lines represent the interaction between different proteins. Circular arrows indicate self-interaction. Helicobacter pylori PBP2 structures (7) using Phyre2 (8) . The structural information lacks the juxta-membrane, transmembrane helix and cytoplasmic regions of PBP2. MreC binds to PBP2 and was proposed to switch PBP2 from the "off state" to the "on state" (7) . The distances between the two sphered residues, (blue for Glu157) and (red for Lys60) were calculated based on the structure of PBP2 in the different conformations. b. Schematic representation of PBP2 conformational changes caused by MreC. Left panels: PBP2 stays in the "off state" in the absence of MreC (the distance between the cytoplasmic terminus of RodA and PBP2 is small); middle panels: PBP2 switches to the "on state" after binding MreC (the distance between cytoplasmic terminus of RodA and PBP2 is larger), right panels: MreD suppresses the MreC- RodA and MreC were fused with mCherry, and PBP2 WT and PBP2 L61R were fused with mKO. c. Phase contrast and fluorescence images of cells expressing PBP2 L61R were less sensitive to A22 but hypersensitive to mecillinam in liquid culture. LMC500 strain expressing nothing, or PBP2 WT , or PBP2 L61R were grown in LB medium at 37 °C. IPTG induction (15 μM), and A22 treatment (10 mg·L -1 ) or mecillinam treatment (2 mg·L -1 ) were applied to each culture for 2 mass doublings. Arrows indicate cells that lysed after mecillinam treatment in the PBP2 L61R culture. Scale bar equals 5 μm. d. Spot assay to test the sensitivities of PBP2 WT and PBP2 L61R to A22 (10 mg·L -1 ) and mecillinam (2 mg·L -1 ). 
